Save information for later
Sign Up

Learn About Gastrointestinal Stromal Tumor

What is the definition of Gastrointestinal Stromal Tumor?

A gastrointestinal stromal tumor (GIST) is a type of tumor that occurs in the gastrointestinal tract, most commonly in the stomach or small intestine. This type of tumor is thought to grow from specialized cells found in the gastrointestinal tract called interstitial cells of Cajal (ICCs) or precursors to these cells. Affected individuals can develop one or more tumors. GISTs are usually found in adults between ages 40 and 70; rarely, children and young adults develop this type of tumor.

What are the causes of Gastrointestinal Stromal Tumor?

Genetic changes in one of several genes are involved in the formation of GISTs. About 80 percent of cases are associated with a mutation in the KIT gene, and about 10 percent of cases are associated with a mutation in the PDGFRA gene. Mutations in the KIT and PDGFRA genes are associated with both familial and sporadic GISTs. Less than 10 percent of cases are SDH-deficient GISTs, which are associated with mutations or other changes in the SDHA, SDHB, SDHC, or SDHD gene. SDH-deficient GIST can be familial or sporadic. A small number of people with a GIST have mutations in other genes.

How prevalent is Gastrointestinal Stromal Tumor?

Approximately 5,000 new cases of GIST are diagnosed in the United States each year. SDH-deficient GIST accounts for about 5 to 7 percent of cases. However, GISTs may be more common than the estimate because small tumors may remain undiagnosed.

Is Gastrointestinal Stromal Tumor an inherited disorder?

Most cases of GIST are sporadic and are not inherited. These cases are associated with a somatic mutation, which is a genetic change that occurs only in the tumor cells and occurs during a person's lifetime.

Who are the top Gastrointestinal Stromal Tumor Local Doctors?
Mark A. Dickson
Elite in Gastrointestinal Stromal Tumor
Hematology Oncology | Hematology | Oncology
Elite in Gastrointestinal Stromal Tumor
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

Mark Dickson is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Dickson is rated as an Elite provider by MediFind in the treatment of Gastrointestinal Stromal Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Endoscopy.

Richard F. Riedel
Elite in Gastrointestinal Stromal Tumor
Elite in Gastrointestinal Stromal Tumor

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Richard Riedel is an Oncologist in Durham, North Carolina. Dr. Riedel is rated as an Elite provider by MediFind in the treatment of Gastrointestinal Stromal Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma. Dr. Riedel is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Gastrointestinal Stromal Tumor
Hematology Oncology | Hematology | Oncology
Elite in Gastrointestinal Stromal Tumor
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

William Tap is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Tap is rated as an Elite provider by MediFind in the treatment of Gastrointestinal Stromal Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization.

What are the latest Gastrointestinal Stromal Tumor Clinical Trials?
A Randomized, Open Label, Positive Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of the Selected Regimen of Rovadicitinib in Moderate to Severe Chronic Graft-versus-host Disease in Third Line and Beyond

Summary: The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can significantly improve the objective response rate of subjects at week 24.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date: July 14, 2021
Published By: National Institutes of Health